CLR 1404 I-124

Drug Profile

CLR 1404 I-124

Alternative Names: 124I-CLR1404; CLR-124; CLR1404 I-124; I-124-CLR1404; I124-NM404; LIGHT

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan Medical School
  • Developer Cellectar Biosciences; University of Wisconsin-Madison
  • Class Imaging agents; Phospholipids; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Brain cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 21 Mar 2017 Cellectar Biosciences has patent protection for CLR 1404 I-124 in USA
  • 15 Mar 2017 Cellectar Biosciences has patents pending for the use of CLR 1404 I-124 as diagnostic in Japan, Europe and USA
  • 15 Mar 2017 Cellectar Biosciences has patents protection for the use of CLR 1404 I-124 as a diagnostic for ceratin cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top